Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on March 11, 2025
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
GlobeNewswire
·
March 11, 2025
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision …
Cellectar Biosciences to Present at the 37th Annual Roth Conference
GlobeNewswire
·
March 11, 2025
FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today …
Teladoc Health Expands Connected Care Partnerships
GlobeNewswire
·
March 11, 2025
PURCHASE, NY, March 11, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the expansion of its connected care partnerships across new care categories including digestive health, centers of excellence, …
Better Life Partners Expands into North Carolina with Whole-Person Care for Substance Use Disorders
GlobeNewswire
·
March 11, 2025
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Better Life Partners is expanding its mission of compassionate, community-based care to North Carolina, and now offers virtual and in-person treatment for opioid and alcohol use disorders. With a …
PDS Biotech Leadership to Participate in March Conferences
GlobeNewswire
·
March 11, 2025
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
GlobeNewswire
·
March 11, 2025
NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, …
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
GlobeNewswire
·
March 11, 2025
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's …
Aventon announces the All-New Abound LR ﹣ The Next Generation Cargo eBike
GlobeNewswire
·
March 11, 2025
Brea, CA, March 11, 2025 (GLOBE NEWSWIRE) -- Brea, CA – March 11, 2025 – Aventon, an industry leader in electric bicycles, is excited to introduce the all-new Abound LR(Long Rack) to the Abound family. With the popularity and success from the original …
Advancial Gives $30,865.97 Donation to Children’s HealthSM
GlobeNewswire
·
March 11, 2025
Plano, TX, March 11, 2025 (GLOBE NEWSWIRE) -- On Tuesday, February 18 Advancial Federal Credit Union presented Children’s Health, one of the largest and most prestigious health care institutions in the country and the leading pediatric health care system …
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
GlobeNewswire
·
March 11, 2025
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage …
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
GlobeNewswire
·
March 11, 2025
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for …
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
March 11, 2025
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation …
AmMax Bio Announces Presentation at BIO-Europe Spring 2025
GlobeNewswire
·
March 11, 2025
REDWOOD CITY, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that Laura Zhu, Ph.D., MBA, the Company’s Chief Business …
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
GlobeNewswire
·
March 11, 2025
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye …
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
GlobeNewswire
·
March 11, 2025
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE …
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
GlobeNewswire
·
March 11, 2025
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), …
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 11, 2025
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for …
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
GlobeNewswire
·
March 11, 2025
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N …
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
GlobeNewswire
·
March 11, 2025
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, …
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
GlobeNewswire
·
March 11, 2025
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1 …